Intelligent Bio Solutions Stock Beta
| INBS Stock | USD 1.63 0.02 1.24% |
Intelligent Bio Solutions fundamentals help investors to digest information that contributes to Intelligent Bio's financial success or failures. It also enables traders to predict the movement of Intelligent Stock. The fundamental analysis module provides a way to measure Intelligent Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intelligent Bio stock.
Intelligent | Beta |
Intelligent Bio Solutions Company Beta Analysis
Intelligent Bio's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Intelligent Bio Beta | 4.72 |
Most of Intelligent Bio's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intelligent Bio Solutions is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Intelligent Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Intelligent Bio is extremely important. It helps to project a fair market value of Intelligent Stock properly, considering its historical fundamentals such as Beta. Since Intelligent Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Intelligent Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Intelligent Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Intelligent Bio Solutions has a Beta of 4.724. This is much higher than that of the Health Care Equipment & Supplies sector and 228.06% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Intelligent Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intelligent Bio's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intelligent Bio could also be used in its relative valuation, which is a method of valuing Intelligent Bio by comparing valuation metrics of similar companies.Intelligent Bio is currently under evaluation in beta category among its peers.
Intelligent Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Intelligent Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Intelligent Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Intelligent Bio's value.| Shares | Citigroup Inc | 2024-06-30 | 0.0 | Headlands Technologies Llc | 2024-06-30 | 0.0 | Jpmorgan Chase & Co | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Alyeska Investment Group, L.p. | 2024-09-30 | 206.2 K | Cvi Holdings Llc | 2024-06-30 | 79.8 K | Geode Capital Management, Llc | 2024-09-30 | 22.7 K | Vanguard Group Inc | 2024-09-30 | 15.5 K | Ubs Group Ag | 2024-06-30 | 8.3 K | Adar1 Capital Management Llc | 2024-09-30 | 5.4 K | Tower Research Capital Llc | 2024-06-30 | 654 |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Intelligent Bio will likely underperform.
Intelligent Fundamentals
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (3.86) % | ||||
| Current Valuation | 3.97 M | ||||
| Shares Outstanding | 4.39 M | ||||
| Shares Owned By Insiders | 3.01 % | ||||
| Shares Owned By Institutions | 14.38 % | ||||
| Number Of Shares Shorted | 564.62 K | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 2.30 X | ||||
| Revenue | 3.11 M | ||||
| Gross Profit | 326.67 K | ||||
| EBITDA | (8.81 M) | ||||
| Net Income | (10.19 M) | ||||
| Cash And Equivalents | 8.28 M | ||||
| Cash Per Share | 0.56 X | ||||
| Total Debt | 871.44 K | ||||
| Current Ratio | 2.33 X | ||||
| Book Value Per Share | 2.41 X | ||||
| Cash Flow From Operations | (9.57 M) | ||||
| Short Ratio | 1.25 X | ||||
| Earnings Per Share | (2.30) X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 50 | ||||
| Beta | 4.72 | ||||
| Market Capitalization | 6.14 M | ||||
| Total Asset | 13.78 M | ||||
| Retained Earnings | (51.96 M) | ||||
| Working Capital | 3.08 M | ||||
| Net Asset | 13.78 M |
About Intelligent Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intelligent Bio Solutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intelligent Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intelligent Bio Solutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Intelligent Stock Analysis
When running Intelligent Bio's price analysis, check to measure Intelligent Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intelligent Bio is operating at the current time. Most of Intelligent Bio's value examination focuses on studying past and present price action to predict the probability of Intelligent Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intelligent Bio's price. Additionally, you may evaluate how the addition of Intelligent Bio to your portfolios can decrease your overall portfolio volatility.